This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hruban, R. H. Articles by Tuveson, D. A. Search for Related Content PubMed PubMed Citation Articles by Hruban, R. H. Articles by Tuveson, D. A.

Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and Recommendations

Ralph H. Hruban^1,2, N. Volkan Adsay⁵, Jorge Albores-Saavedra⁶, Miriam R. Anver⁷, Andrew V. Biankin³, Gregory P. Boivin⁸, Emma E. Furth⁹, Toru Furukawa¹², Alison Klein^1,2, David S. Klimstra¹³, Gnter Klppel¹⁴, Gregory Y. Lauwers¹⁵, Daniel S. Longnecker¹⁷, Jutta Lttges¹⁸, Anirban Maitra^1,2,4, G. Johan A. Offerhaus¹⁹, Lucía Pérez-Gallego²⁰, Mark Redston¹⁶ and David A. Tuveson^10,11

Departments of ¹ Pathology, ² Oncology, and ³ Surgery and ⁴ the Institute for Genetic Medicine, The Sol Goldman Center for Pancreatic Cancer Research, The Johns Hopkins Medical Institutions, Baltimore, Maryland; ⁵ Department of Pathology, Wayne State University, Harper Hospital, Detroit, Michigan; ⁶ Department of Pathology, Louisiana State University, Shreveport, Louisiana; ⁷ Pathology/Histochemistry Laboratory, SAIC Frederick, Inc., Frederick, Maryland; ⁸ Department of Pathology, The University of Cincinnati, Cincinnati, Ohio; Departments of ⁹ Pathology, ¹⁰ Medicine, and ¹¹ Cancer Biology, Abramson Family Cancer Research Institute, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; ¹² International Research and Educational Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan; ¹³ Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York; ¹⁴ Department of Pathology, University of Kiel, Kiel, Germany; ¹⁵ Department of Pathology, Massachusetts General Hospital; ¹⁶ Department of Pathology, Brigham and Woman's Hospital, Boston, Massachusetts; ¹⁷ Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hamsphire; ¹⁸ Department of Pathology, Teaching Hospital University Homburg, Saarbrücken, Germany; ¹⁹ Department of Pathology, The Academic Medical Center, Amsterdam, the Netherlands; and ²⁰ Comparative Pathology, Spanish National Cancer Centre, Madrid, Spain

Requests for reprints: Ralph H. Hruban, The Sol Goldman Pancreatic Cancer Center, The Johns Hopkins Hospital, 401 North Broadway, Weinberg 2242, Baltimore, MD 21231. Phone: 410-955-9132; Fax: 410-955-0115; E-mail: rhruban{at}jhmi.edu.

Several diverse genetically engineered mouse models of pancreatic exocrine neoplasia have been developed. These mouse models have a spectrum of pathologic changes; however, until now, there has been no uniform nomenclature to characterize these changes. An international workshop, sponsored by The National Cancer Institute and the University of Pennsylvania, was held from December 1 to 3, 2004 with the goal of establishing an internationally accepted uniform nomenclature for the pathology of genetically engineered mouse models of pancreatic exocrine neoplasia. The pancreatic pathology in 12 existing mouse models of pancreatic neoplasia was reviewed at this workshop, and a standardized nomenclature with definitions and associated images was developed. It is our intention that this nomenclature will standardize the reporting of genetically engineered mouse models of pancreatic exocrine neoplasia, that it will facilitate comparisons between genetically engineered mouse models and human pancreatic disease, and that it will be broad enough to accommodate newly emerging mouse models of pancreatic neoplasia. (Cancer Res 2006; 66(1): 95-106)

This article has been cited by other articles:

				P. A. Philip, M. Mooney, D. Jaffe, G. Eckhardt, M. Moore, N. Meropol, L. Emens, E. O'Reilly, M. Korc, L. Ellis, et al. Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment J. Clin. Oncol., November 20, 2009; 27(33): 5660 - 5669. [Abstract] [Full Text] [PDF]

				K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, D. Allard, et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer Science, June 12, 2009; 324(5933): 1457 - 1461. [Abstract] [Full Text] [PDF]

				J. Khasawneh, M. D. Schulz, A. Walch, J. Rozman, M. H. de Angelis, M. Klingenspor, A. Buck, M. Schwaiger, D. Saur, R. M. Schmid, et al. Inflammation and mitochondrial fatty acid {beta}-oxidation link obesity to early tumor promotion PNAS, March 3, 2009; 106(9): 3354 - 3359. [Abstract] [Full Text] [PDF]

				C. Shi, S.-M. Hong, P. Lim, H. Kamiyama, M. Khan, R. A. Anders, M. Goggins, R. H. Hruban, and J. R. Eshleman KRAS2 Mutations in Human Pancreatic Acinar-Ductal Metaplastic Lesions Are Limited to Those with PanIN: Implications for the Human Pancreatic Cancer Cell of Origin Mol. Cancer Res., February 1, 2009; 7(2): 230 - 236. [Abstract] [Full Text] [PDF]

				E. S. Seeley, C. Carriere, T. Goetze, D. S. Longnecker, and M. Korc Pancreatic Cancer and Precursor Pancreatic Intraepithelial Neoplasia Lesions Are Devoid of Primary Cilia Cancer Res., January 15, 2009; 69(2): 422 - 430. [Abstract] [Full Text] [PDF]

				J.-P. De La O, L. L. Emerson, J. L. Goodman, S. C. Froebe, B. E. Illum, A. B. Curtis, and L. C. Murtaugh Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia PNAS, December 2, 2008; 105(48): 18907 - 18912. [Abstract] [Full Text] [PDF]

				N. Habbe, G. Shi, R. A. Meguid, V. Fendrich, F. Esni, H. Chen, G. Feldmann, D. A. Stoffers, S. F. Konieczny, S. D. Leach, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice PNAS, December 2, 2008; 105(48): 18913 - 18918. [Abstract] [Full Text] [PDF]

				G Feldmann, N Habbe, S Dhara, S Bisht, H Alvarez, V Fendrich, R Beaty, M Mullendore, C Karikari, N Bardeesy, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer Gut, October 1, 2008; 57(10): 1420 - 1430. [Abstract] [Full Text] [PDF]

				F Marrache, S Pendyala, G Bhagat, K S Betz, Z Song, and T C Wang Role of bone marrow-derived cells in experimental chronic pancreatitis Gut, August 1, 2008; 57(8): 1113 - 1120. [Abstract] [Full Text] [PDF]

				B. Seidler, A. Schmidt, U. Mayr, H. Nakhai, R. M. Schmid, G. Schneider, and D. Saur A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors PNAS, July 22, 2008; 105(29): 10137 - 10142. [Abstract] [Full Text] [PDF]

				J. P. Morton, D. S. Klimstra, M. E. Mongeau, and B. C. Lewis Trp53 Deletion Stimulates the Formation of Metastatic Pancreatic Tumors Am. J. Pathol., April 1, 2008; 172(4): 1081 - 1087. [Abstract] [Full Text] [PDF]

				C. E. Clark, S. R. Hingorani, R. Mick, C. Combs, D. A. Tuveson, and R. H. Vonderheide Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion Cancer Res., October 1, 2007; 67(19): 9518 - 9527. [Abstract] [Full Text] [PDF]

				G. R. van den Brink Hedgehog Signaling in Development and Homeostasis of the Gastrointestinal Tract Physiol Rev, October 1, 2007; 87(4): 1343 - 1375. [Abstract] [Full Text] [PDF]

				K. Kojima, S. M. Vickers, N. V. Adsay, N. C. Jhala, H.-G. Kim, T. R. Schoeb, W. E. Grizzle, and C. A. Klug Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia Cancer Res., September 1, 2007; 67(17): 8121 - 8130. [Abstract] [Full Text] [PDF]

				M. Aichler, H. Algul, D. Behne, G. Holzlwimmer, B. Michalke, L. Quintanilla-Martinez, J. Schmidt, R. M. Schmid, and M. Brielmeier Selenium status alters tumour differentiation but not incidence or latency of pancreatic adenocarcinomas in Ela-TGF-{alpha} p53+/ mice Carcinogenesis, September 1, 2007; 28(9): 2002 - 2007. [Abstract] [Full Text] [PDF]

				H. Funahashi, M. Satake, D. Dawson, N.-A. Huynh, H. A. Reber, O. J. Hines, and G. Eibl Delayed Progression of Pancreatic Intraepithelial Neoplasia in a Conditional KrasG12D Mouse Model by a Selective Cyclooxygenase-2 Inhibitor Cancer Res., August 1, 2007; 67(15): 7068 - 7071. [Abstract] [Full Text] [PDF]

				L. Zhu, G. Shi, C. Max. Schmidt, R. H. Hruban, and S. F. Konieczny Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia Am. J. Pathol., July 1, 2007; 171(1): 263 - 273. [Abstract] [Full Text] [PDF]

				C. Carriere, E. S. Seeley, T. Goetze, D. S. Longnecker, and M. Korc The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia PNAS, March 13, 2007; 104(11): 4437 - 4442. [Abstract] [Full Text] [PDF]

				O. Strobel, Y. Dor, A. Stirman, A. Trainor, C. Fernandez-del Castillo, A. L. Warshaw, and S. P. Thayer beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivo PNAS, March 13, 2007; 104(11): 4419 - 4424. [Abstract] [Full Text] [PDF]

				N. Bardeesy, K.-h. Cheng, J. H. Berger, G. C. Chu, J. Pahler, P. Olson, A. F. Hezel, J. Horner, G. Y. Lauwers, D. Hanahan, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes & Dev., November 15, 2006; 20(22): 3130 - 3146. [Abstract] [Full Text] [PDF]

				H. Ijichi, A. Chytil, A. E. Gorska, M. E. Aakre, Y. Fujitani, S. Fujitani, C. V.E. Wright, and H. L. Moses Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes & Dev., November 15, 2006; 20(22): 3147 - 3160. [Abstract] [Full Text] [PDF]

				M. Pasca di Magliano, S. Sekine, A. Ermilov, J. Ferris, A. A. Dlugosz, and M. Hebrok Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes & Dev., November 15, 2006; 20(22): 3161 - 3173. [Abstract] [Full Text] [PDF]

				G. K. Abou-Alfa, R. Letourneau, G. Harker, M. Modiano, H. Hurwitz, N. S. Tchekmedyian, K. Feit, J. Ackerman, R. L. De Jager, S. G. Eckhardt, et al. Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4441 - 4447. [Abstract] [Full Text] [PDF]

				K. P. Olive and D. A. Tuveson The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res., September 15, 2006; 12(18): 5277 - 5287. [Abstract] [Full Text] [PDF]

				A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]

				D.A. TUVESON and S.R. HINGORANI Ductal Pancreatic Cancer in Humans and Mice Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 65 - 72. [Abstract] [PDF]